Research Radartracking 1,762 published studies · 471 human · 11 safety signals · 58 clinical trials · 44 cancer pages · updated Sep 2026Open the Research Map →

Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language. A person reviews each one; registered human trials and meta-analyses that pass every automated check post without waiting for that review.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract. A person reviews them; the strongest tier — registered human trials and meta-analyses that pass every automated check — is posted first and reviewed after. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.
Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:
Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism
Showing studies that mention “mucinous ovarian tumors”.
1 of 200 studies
Human · observationalMechanismMixed resultsLimited evidenceTier 3 · early humann = 923

Folate receptor alpha (FRα) expression in tubo-ovarian and endometrial tumors: a study of 923 cases

The journal of pathology. Clinical research · Mar 2026 · immunohistochemical study on tissue microarrays using the VENTANA FOLR1 CDx assay with standardized scoring criteria

tubo-ovarian tumorsendometrial tumorshigh-grade serous carcinoma (HGSC)low-grade serous carcinoma (LGSC)endometrial serous carcinomaserous borderline tumorendometrioid ovarian carcinomaclear cell ovarian carcinomamucinous ovarian tumorssex cord-stromal tumorsendometrial endometrioid carcinomasundifferentiated carcinomadedifferentiated carcinomaendometrial clear cell carcinoma

The study examined folate receptor alpha (FRα) expression by immunohistochemistry on tissue microarrays of 923 tubo-ovarian and endometrial tumors using the VENTANA FOLR1 CDx assay and standardized scoring. They found FRα expression most commonly in serous carcinomas (45% of HGSC, 25% LGSC) and less commonly in some endometrial serous and serous borderline tumors, while many other ovarian and endometrial tumor types were negative or rarely positive. The work is descriptive and does not report clinical outcomes or functional testing.

Reported effects: HGSC positive cases 45% · Low-grade serous carcinoma positive cases 25% · +4 more

Key findings
  • HGSC (high-grade serous carcinoma): 45% positive cases
  • Low-grade serous carcinoma: 25% positive cases
  • Endometrial serous carcinoma: 11% positive cases
  • Serous borderline tumor: 10% positive cases
  • Endometrioid ovarian carcinoma: 2% positive cases
  • Clear cell ovarian carcinoma: 1% positive cases
  • Mucinous ovarian tumors, sex cord-stromal tumors, endometrial endometrioid carcinomas, undifferentiated and dedifferentiated carcinomas, and endometrial clear cell carcinomas were reported as negative
Limitations: Descriptive immunohistochemistry only — no functional assays or correlation with clinical outcomes reported in the abstract; Use of tissue microarrays may under-represent intratumoral heterogeneity; Cross-sectional/tissue-based study without longitudinal or therapeutic response data.

AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text